Menu
Recruiting NCT06535802

iCCaRE Consortium Pilot Project 1: Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed Black Men

Observational Prostate Carcinoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Focus group, Clinician Interviews, Intervention testing, Survey.
Who it may be relevant to
Registry conditions: Prostate Carcinoma. Basic parameters: up to 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This study is being done to determine the acceptance and effectiveness of a virtual robot assistant model at a urology clinic.

Detailed description

PRIMARY OBJECTIVES:

I. Plan and develop a PPCD iCCaRE ViRA model that will provide social determinants of health (SDOH) navigation services, psycho-oncology support and emotional support using qualitative formative research.

II: Establish the acceptance and usability of the iCCaRE ViRA among 50 African American/Black men (AA/BM) at local Jacksonville sites.

OUTLINE: This is an observational study. Participants are assigned to 1 of 4 cohorts.

COHORT I: Consumer advocates attend a focus group on study.

COHORT II: Clinicians complete interviews on study.

COHORT III: CaP survivors test the virtual health intervention, complete a survey, and attend a focus group on study.

COHORT IV: Patients complete surveys and participate in the virtual health intervention on study. Patients complete survey and an interview during follow up.

Interventions

  • Other Focus group
    Attend a focus group session
  • Other Clinician Interviews
    Participate in clinician interviews
  • Other Intervention testing
    Test the virtual health intervention
  • Other Survey
    Complete a follow-up survey
  • Other Follow-up Interview
    Participate in a follow-up interview
  • Other Virtual Health Intervention
    Participate in the virtual health intervention

Primary outcome measures

  • Point of Prostate Cancer Diagnosis (PPCD) iCCaRE Virtual Reality Assistant (ViRA) model [Time frame: Up to 4 months]
  • Acceptance of the iCCaRE ViRA [Time frame: Baseline; follow-up interview 3-4 months post visit]
  • Usability of the iCCaRE ViRA [Time frame: Baseline; follow-up interview 3-4 months post visit]

Eligibility criteria

Inclusion criteria

  • AIM 1: iCCaRE Consortium consumer advocates
  • Clinicians who are part of the Translational Research \& Clinical Intervention Services (TRaCIS)
  • AIM 2 ALPHA TESTING: iCCaRE consumer advocates \[2 Community Advisory Board (CAB) and 1 non-CAB\]
  • AIM 2 BETA TESTING-PATIENTS:
  • An African American/Black male
  • A patient who has been diagnosed with prostate cancer in Florida at any time in their life, and/or within the previous 6 months has had an abnormal Prostate-Specific Antigen (PSA) lab value and/or Digital Rectal Examination (DRE)
  • Minimum age of 30 years old
  • Consent to participating in the intervention

Exclusion criteria

  • AIM 2 BETA TESTING-PATIENTS:
  • Patients who are not African American/Black males
  • Patients not diagnosed with prostate cancer in Florida at any time in their life, or within the previous 6 months has not had a normal PSA lab value and/or DRE
  • Older than 80 years old
  • Are not willing to consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • Mayo Clinic in Florida — Jacksonville

Identifiers

NCT: NCT06535802 · MC220501 · W81XWH2210968 · NCI-2024-05156 · MC220501 · 22-001412

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗